Enteric opportunistic infections in patients with inflammatory bowel disease receiving biologic therapies: a retrospective cohort study
Related Experiment Video
Updated: Jan 8, 2026
Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
Ting-Chieh Huang1,2, Tony Kou1,2,3, Chia-Jung Kuo1,2,3,4,5
1College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
Background:
Biologic therapy has improved outcomes in inflammatory bowel disease (IBD) but may predispose patients to enteric opportunistic infections. Asian data comparing infection risk across biologic classes remain scarce. We therefore assessed the incidence of Clostridioides difficile infection (CDI), Clostridium innocuum (CI) infection, and cytomegalovirus (CMV) colitis in IBD patients treated with Vedolizumab (VDZ), anti-tumor necrosis factor agents (anti-TNF), or Ustekinumab (UST).
Methods:
This single‑center, retrospective cohort study included IBD patients who initiated VDZ, anti‑TNF (infliximab or adalimumab) or UST at Chang Gung IBD Center between January 2017 and December 2024. Opportunistic infection was defined as: (i) toxin‑gene PCR-positive CDI, (ii) CI isolated in stool/colonic culture, or (iii) CMV‑positive immunohistochemistry on intestinal biopsy. Incidence rates were expressed per 100 patient‑years. Infection‑free survival was compared with Kaplan-Meier analysis and log‑rank testing. Multivariable logistic regression identified independent predictors of CDI.
Results:
A total of 614 patients (377 Crohn's disease; 237 ulcerative colitis) contributed 941 patient‑years of follow‑up. The incidences per 100 patient-years were 3.51 for CDI, 0.85 for CI, and 3.30 for CMV colitis. CDI and CI risks were comparable across VDZ, anti‑TNF and UST cohorts. CMV colitis was significantly more common with anti‑TNF therapy (5.9%) than with VDZ (3.4%) or UST (0.5%) (p = 0.020). Independent predictors of CDI were an acute IBD flare (odds ratio [OR] 3.64; 95% confidence interval 1.91-6.91), concurrent CMV colitis (OR 6.34; 95% confidence interval 2.03-19.8) and CI infection (OR 7.79; 95% confidence interval 1.40-43.3).
Conclusion:
VDZ and UST were not associated with excess CDI, CI or CMV risk, whereas anti‑TNF therapy conferred a higher burden of CMV colitis. Heightened infection surveillance is warranted during acute flares and refractory disease courses.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
07:06Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...